Arthur T. Sands is a distinguished figure in the biopharmaceutical industry, currently serving as the President, Chief Executive Officer, and Director at Nurix Therapeutics Inc. Dr. Sands has a robust background in medicine and biotechnology, having earned his M.D. from Harvard Medical School and a Ph.D. in Genetics from Harvard University. His career spans several high-profile roles, including his tenure as the President and CEO of ICOS Corporation, where he played a pivotal role in the development and commercialization of the blockbuster drug Tadalafil (Cialis). Prior to joining Nurix, Dr. Sands held significant positions at Eli Lilly and Company, where he served as the Executive Vice President of Global Research and Development, and as the President of Lilly Bio-Medicines. During his time at Lilly, he was instrumental in advancing the company’s pipeline and bringing several new drugs to market, showcasing his strategic leadership and scientific acumen. His work has been recognized with numerous awards and honors, reflecting his contributions to the field of medicine and his commitment to improving patient outcomes. At Nurix Therapeutics, Dr. Sands leads the company’s efforts to develop novel therapies based on the modulation of cellular protein levels. His role involves overseeing the strategic direction of the company, driving innovation, and fostering a culture of scientific excellence. Under his leadership, Nurix has made significant strides in advancing its pipeline of drug candidates, particularly in the areas of oncology and inflammation. Dr. Sands’ vision for Nurix is to become a leader in the emerging field of protein degradation, leveraging the company’s proprietary platforms to address unmet medical needs and ultimately improve the lives of patients worldwide.